GuruFocus Premium Membership

Serving Intelligent Investors since 2004. Only 96 cents a day.

Free Trial

Free 7-day Trial
All Articles and Columns »

Weekly Guru Bargains Highlights: PBR

February 11, 2014 | About:
GuruFocus

GuruFocus

341 followers

According to GuruFocus updates, these stocks have declined the most since Gurus have bought.

Petroleo Brasileiro SA Petrobras (PBR): Down 21% Since Brian Rogers (Trades, Portfolio) Bought in the Quarter Ended on 2013-09-30

Brian Rogers (Trades, Portfolio) added to his holdings in exploration and production company Petroleo Brasileiro SA Petrobras by 43.75% during the quarter ended 09/30/2013. His purchase prices were between $12.13 and $16.37, with an estimated average price of $14.24. Since then the prices of Petroleo Brasileiro SA Petrobras shares have declined by 21% from the estimated average. Brian Rogers (Trades, Portfolio) owned 11,500,000 shares of Petroleo Brasileiro SA Petrobras as of 09/30/2013.

Petroleo Brasileiro SA Petrobras was incorporated in 1953 to conduct the Brazilian federal government's hydrocarbon activities. Petroleo Brasileiro SA Petrobras has a market cap of $76.31 billion; its shares were traded at around $11.70 with a P/E ratio of 5.90 and P/S ratio of 0.50. Petroleo Brasileiro SA Petrobras had an annual average earnings growth of 10.50% over the past 10 years.

David Dreman (Trades, Portfolio) owns 310,065 shares as of 09/30/2013, which accounts for 0.43% of the $1.11 billion portfolio of Dreman Value Management. Ray Dalio (Trades, Portfolio) owns 509,400 shares as of 09/30/2013, which accounts for 0.066% of the $11.87 billion portfolio of Bridgewater Associates.

For the complete list of stocks that are Guru bargains, go to: Value Bargains of Gurus.


Rating: 4.0/5 (3 votes)

Comments

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK